Skip to main content

Dianthus Therapeutics, Inc.

DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001690585

In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Dianthus Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of DNTH: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders9793−4
Shares37.5M37.9M+444.6K (+1.2%)
Value$366.3M$276.0M−$90.4M (−24.7%)

New holders (15)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to DNTH in Q3 2021
InstitutionSharesValue% of portfolio
Woodline Partners LP515,670$3.75M0.06%
Eversept Partners, LP198,879$1.45M0.12%
First Trust Advisors LP52,458$382.0K0.00%
AQR Capital Management LLC37,739$275.0K0.00%
Renaissance Technologies LLC24,300$177.0K0.00%
Hershey Trust Co20,290$148.0K0.00%
HRT Financial LP19,585$142.0K0.00%
Nisa Investment Advisors, LLC15,395$112.0K0.00%
Parametric Portfolio Associates LLC15,205$111.0K0.00%
Vontobel Holding Ltd.14,790$108.0K0.00%
SG Americas Securities, LLC14,639$107.0K0.00%
Engineers Gate Manager LP10,100$74.0K0.00%
Rockefeller Capital Management L.P.3,600$26.0K0.00%
Signaturefd, LLC79$1.00K0.00%
Advisor Group Holdings, Inc.123$1.00K0.00%

Sold out (19)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.